Advertisement
Latest print edition American Medical News
 
HEALTH

Speaking the language of vaccines (ICAAC and IDSA joint meeting)

Easing parents' fears about vaccine safety may mean moving beyond answers couched with scientific caveats.

By Susan J. Landers, amednews staff. Dec. 15, 2008.

  • PRINT|
  • E-MAIL|
  • RESPOND|
  • REPRINTS|
  • Share SHARE Share

Childhood vaccines are entangled in a vast public controversy, and doctors often find themselves helping perplexed parents sort through misinformation before making a decision on immunization.

Mindful of these discussions, a panel of physicians and journalists offered pointers to those on the front lines during the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America, held Oct. 25-28 in Washington, D.C.

Panelist Paul Offit, MD, director of the Vaccine Education Center at the Children's Hospital in Philadelphia, believes one way to address parents' fears is for physicians to sharpen their message and stop using the scientific language of the many reports that have found no link between autism and the measles, mumps and rubella vaccine.

A developer of the vaccine RotaTeq and author of Autism's False Prophets: Bad Science, Risky Medicine, and the Search for a Cure, Dr. Offit said the language of science can confuse lay people. Instead, physicians should ratchet up the message and state their point emphatically -- that the vaccine does not cause autism, he said.

"After you have done 10 studies and spent millions of dollars looking for the association between autism and MMR, I think you can be a little more definitive in your language."

One conversation at a time

Simon Dobson, MD, clinical associate professor of pediatrics at British Columbia Children's Hospital in Vancouver, often has what he calls the "eyeball-to-eyeball" conversation with a parent who is concerned about immunizations.

He recommends patience and good listening skills. Parents are often worried about something close to home, he said. "If you can nail that family myth or whatever it is that concerns them, the rest is easy."

A drop in MMR vaccination rates in the United Kingdom has led to outbreaks of measles.

Most worried parents relate stories about growing up knowing a child who had autism or another disability. After all, many panelists noted, because of vaccines, measles and other serious childhood diseases have never been seen by parents, or even many physicians, while autism is much more in evidence.

But the more difficult cases involve parents who have been "bombarded by the media," Dr. Dobson said. "They just don't know what to do and are paralyzed by indecision."

He, too, recommends cutting back on scientific evidence when discussing vaccine benefits. "I would go on and on about the benefits of the vaccine and the risk of the disease, and parents would get a glazed look."

Instead, he tries to tap parents' imaginations and urge them to think about what could happen if they forgo vaccines for their children. The anti-vaccine people use anecdotes, he said. "But we get the anecdotes beaten out of us in medical school." Nevertheless, he noted, "I can tell a tragic story. It has a great impact on parents."

For example, he asks parents to imagine what might happen if their child grows up to do good works in far-off countries where diseases such as polio are still endemic. If the child is not immunized, he or she could become infected, he relates.

"Parents may think of me as pompous -- a windbag in the pay of the government, big pharma and big business -- but they do respect my opinion," he said.

No link has been found between autism and the MMR vaccine.

Also remember the conversations can take place over several office visits, Dr. Dobson said. "You don't need to do it all in one go. This is particularly true in the primary care setting."

British journalist Vivienne Parry, who also served on the UK Joint Committee on Vaccination and Immunisation, noted that the drop in the MMR vaccination rate in her country has led to outbreaks of disease. "People are much more afraid of autism than they are of measles."

Parry urged physicians to stand up in support of vaccines. "It has distressed me to see Paul Offit out there by himself," she said, referring to Dr. Offit's outspoken defense of vaccine safety, which has made him a target of anti-vaccine activists and the recipient of death threats. "Where are the other physicians supporting him?"

Physicians need to engage patients with simple and emotional language, she added. "You need to understand where the problems are coming from. The fears are natural. You need to think about that when you are communicating with patients."

Dr. Offit said he would like to see a recasting of the characters in this ongoing drama. Now, the anti-vaccine people are often identified as the only ones who care about children. "I just wish the story was told a different way," he said. As a result of the suspicion being raised that vaccines are connected to autism, "we continue to divert resources away from more promising leads."

Back to top


 ADDITIONAL INFORMATION: 

MRSA on the rise

Rates of outpatient visits for skin and soft-tissue infections have increased in recent years, mirroring the spread of methicillin-resistant Staphylococcus aureus in the community. Researchers tallied visits to physicians' offices, hospital outpatient departments and emergency departments using data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, both 1997-2005. Numbers show annual visits per 1,000 population. Abscess and cellulitis are hallmark infections associated with MRSA.

All skin and
soft-tissue infections
Abscess and
cellulitis
19973217
19983520
19993723
20003321
20013523
20024022
20034327
20044932
20054832

Source: "National Trends in Ambulatory Visits and Antibiotic Prescribing for Skin and Soft-Tissue Infections," Archives of Internal Medicine, July 28 (http://archinte.ama-assn.org/cgi/reprint/168/14/1585.pdf)

Back to top


Alternative MRSA drugs are the focus of 2 trials

Staphylococcus aureus is a smart bug. It has figured out how to evade most of the antibiotics physicians have thrown at it and doesn't show signs of dumbing down soon, said presenters at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America. The meeting was held in Washington, D.C., Oct. 25-28.

The resistant forms of S. aureus -- referred to as methicillin-resistant Staphylococcus aureus -- are responsible for large increases in the numbers of patients with skin and soft-tissue infections who are showing up in physician's offices and emergency departments nationwide. A recent analysis of records from outpatient settings showed a doubling of the number of abscesses or cellulitis, which are MRSA hallmarks -- from 4.6 million to 9.6 million -- from 1997 to 2005. The highest rates were seen among children in urban emergency departments.

The community is where MRSA is now taking its greatest toll, said pediatric diseases specialist Robert Daum, MD, professor of pediatrics at the University of Chicago. He spoke during a symposium on treatment and prevention techniques.

The first step in treatment is draining the pus, noted Rachel Gorwitz, MD, MPH, a medical epidemiologist at the Centers for Disease Control and Prevention. Beyond that, the CDC, the AMA and IDSA advise in a joint statement sending the wound drainage for culture and susceptibility testing and, if signs of infection persist, prescribing an appropriate antibiotic.

However, not all physicians are on the same page when it comes to treatment beyond incision and drainage, noted Dr. Daum.

An array of opinions

An article in the Oct. 9 New England Journal of Medicine reported the results of a poll in which readers were asked to vote for the best of three treatment options for a 20-year-old college basketball player with a tender, red area on the right buttock.

In response, 41% of the more than 11,000 votes cast favored incision and drainage plus an oral antimicrobial agent against MRSA; 31% favored incision and drainage alone; and 28% favored incision and drainage plus an oral antimicrobial agent active against methicillin susceptible S. aureus.

Given this state of confusion and the scarcity of effective medications, the National Institutes of Health recently launched two clinical trials to determine whether older, off-patent antibiotics such as clindamycin and trimethoprim/sulfamethoxazole are effective treatments for the management of uncomplicated community-acquired MRSA.

But Dr. Daum would like to move the agenda from treatment to prevention with the development of an S. aureus vaccine. The need is apparent, he said. The rate of MRSA infections is now twice as high as were the number of Haemophilus influenzae infections several decades ago when the decision was made to develop that vaccine, he noted. "Now Haemophilus is largely gone."

In one possible bright spot, Henry Chambers, MD, a professor of medicine at the University of California, San Francisco, and infectious diseases director at San Francisco General Hospital, reported that the rate of infection from community-acquired MRSA may be dropping after peaking in 2004. "We may be riding the curve down."

Back to top


Treatment tips

From the ICAAC/IDSA joint meeting 2008:

Stopping flu transmission. A study presented at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America examined the effectiveness of steps to stop the transmission of the flu virus. Specifically, wearing masks and using alcohol-based hand sanitizers in a community setting may prevent the spread of seasonal influenza by as much as 50%, according to researchers from the University of Michigan School of Public Health in Ann Arbor. Their finding were presented during a slide session.

The researchers studied more than 1,000 students from seven university residence halls during the 2006-07 flu season and again during the last flu season. Participants were randomly assigned to six weeks of wearing masks; wearing masks and using hand sanitizers; or serving as controls and using no protections.

From the third week of the study on, both the mask and mask/hand sanitizer interventions showed a significant or nearly significant reduction in the rate of influenza-like illness symptoms in comparison to the control group.

The observed reduction rate remained even after adjusting for gender, race/ethnicity, hand-washing practices, sleep quality and flu vaccination, the researchers said.

Infectious waiting room toys. Toys in pediatric waiting rooms were found to harbor remnants of cold viruses even after cleaning with commercially available disinfectant cloths, according to a study conducted at the University of Virginia Children's Hospital in Charlottesville. Rhinovirus was detected most often.

The researchers also found some of the toys that were not contaminated before cleaning, tested positive for viral remains after cleaning. Twenty percent of the toys in the sick child waiting room were contaminated, 17% of the toys in the well child waiting room showed viral remains and, interestingly, no virus was found on any of the toys in the exam rooms.

The study was conducted during fall and winter on three separate dates in a pediatrician's office.

The findings were presented at a slide session.

Back to top


Research findings: Ways to reduce cervical cancer, track rotavirus incidence

New mathematical modeling data show that vaccinating women and girls in the U.S. at ages 12, 19, 25, 35 and 45 against the human papillomavirus could result in a dramatic drop in the number of cases of cervical cancer and pre-cancer.

The results indicated that if 100% of the various age groups were vaccinated, reductions in cervical cancer could reach 53% to 76% among 19-year-olds, 34% to 67% among 25-year-olds, 34% to 63% among 35-year-olds and 20% to 55% among 45-year-olds.

A routine HPV vaccine currently is recommended for 11- and 12-year-old girls with a catch-up vaccine for girls and women ages 13 to 26. The vaccination of women older than 26 has not been approved by the Food and Drug Administration and is not included in Centers for Disease Control and Prevention guidelines.

The findings were presented during a poster session at the October joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America.

Meanwhile, incidence of rotavirus declined sharply in the U.S. in the two years since the licensure in 2006 of RotaTeq, a live, oral vaccine to combat the disease, according to various studies presented at the same meeting.

One study, conducted by researchers at Madison, N.J.-based Quest Diagnostics, found in the three years before the vaccine was licensed, an average of 27,625 tests for rotavirus were performed annually during the December through June peak season. Of these, 7,162 tests were positive. During the most recent peak season -- December 2007 through June 2008 -- 21,873 tests were performed, and 1,703 were positive. The tests were conducted at Quest laboratories nationwide.

A second study conducted by researchers at the University of Massachusetts Medical Center in Worchester also discovered a dramatic decline in the number of laboratory-confirmed cases of rotaviral diarrhea in central Massachusetts within two years of the introduction of the vaccine. The numbers dropped from 65 cases per year on average before the vaccine to three per year on average.

The studies also were presented at poster sessions.

Back to top


Copyright 2008 American Medical Association. All rights reserved.